{"article":{"annotation":{"article_id":"who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026","available_at":"2026-11-20T15:14:56.768224Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"9854812546d861bfd83b544d77a4b2a7cb61584ba0b33effcefc5ce0642365c2","input_sha256":"733846e6b99d82eb7479545edcdf7638c7334de0f06a478994f174312a8a4ff5","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: Health","source_urls":["https://www.who.int/news/item/20-11-2026-better-medicines-for-every-child--gap-f-partners-accelerate-action-on-world-children-s-day"]}],"method":"controlled-rules-v1","rule_id":"health","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=en","category":"health","content":{"key_points":[],"paragraphs":["The World Health Organization and partners in the Global Accelerator for Paediatric Formulations Network, known as GAP-f, issued an update on 20 November 2026 to mark World Children's Day and review ongoing work to expand access to safe, effective and age-appropriate medicines for children. Hosted by WHO, the network brings together institutions across industry, academia, civil society and global health agencies. While noting progress in clinical research and formulation development, the update stressed that significant gaps persist in turning scientific advances into treatments that reach children in all settings.","Central to the network's multi-year work is the GAP-f Strategic Roadmap 2025-2030, anchored by a measurable framework called the 30 by '30 commitment. Under that commitment, GAP-f and its partners aim by 2030 to assess priorities across 10 high-burden diseases, accelerate the development and availability of 10 priority paediatric medicines and strengthen national paediatric medicines ecosystems in 10 countries. The update reaffirmed these three targets as shared benchmarks requiring sustained funding, regulatory coordination and country-level follow-through rather than isolated research projects.","Sylvie Briand, WHO chief scientist and acting assistant director-general for health systems, access and data, underscored the urgency of closing delays in child-focused drug development. She stated that children should not have to wait for medicines designed for their specific clinical needs, adding that aligning global priorities, strengthening paediatric clinical research and helping countries translate innovation into practical access are essential to achieving equitable health outcomes for every child.","The first operational pillar highlighted in the 20 November 2026 update centers on prioritization through WHO's Paediatric Drug Optimization process, known as PADO. Through PADO, GAP-f convenes technical experts and partner organizations to identify priority medicines and child-friendly formulations that address critical gaps in disease prevention and treatment. The network also pointed to a dedicated GAP-f product portfolio designed to consolidate these priorities into a single reference so that academic researchers, pharmaceutical developers and global health funders can concentrate resources on the highest-impact paediatric needs.","The second pillar focuses on generating stronger clinical evidence for children, who have historically been underrepresented in drug trials. GAP-f reported that it is working with partners to map global clinical research site capacity, promote the inclusion of children in clinical studies and encourage more efficient trial designs. To operationalize this effort, the network is assembling a package of clinical research resources combining information on global paediatric clinical trial sites, training materials on trial design and implementation, and cross-stakeholder recommendations on optimal study methodologies.","The third pillar addresses the transition from product development to country-level availability and clinical uptake. Developing an age-appropriate formulation does not guarantee that clinics and families can obtain or afford it without functioning regulatory pathways, procurement systems and national treatment guidelines. GAP-f stated that it works alongside WHO technical departments, Member States and partner organizations to diagnose bottlenecks in country access and support the practical introduction of optimal paediatric formulations.","As a concrete example of regional implementation, WHO highlighted a workshop convened in May 2026 with GAP-f partners in the South-East Asia region focused on strengthening paediatric medicines ecosystems. The gathering brought together national stakeholders from four pilot countries to examine structural barriers and identify workable solutions. Accompanying the World Children's Day update, a new report from the May 2026 workshop documents those findings and outlines practical opportunities for countries to align global prioritization and clinical evidence with local health-system realities.","The update framed paediatric medicines access as a lifecycle challenge spanning early prioritization, clinical trial execution, formulation engineering, regulatory review, financing and health-system delivery. Because no single institution controls every step of that chain, WHO described GAP-f as a coordination platform meant to keep governments, regulators, researchers, product developers, funders and civil society working toward shared milestones rather than fragmented initiatives.","The 20 November 2026 statement is a policy and program progress update rather than an announcement of a specific new drug approval or financing commitment. Measuring whether the 30 by '30 targets are achieved by 2030 will depend on transparent tracking of which 10 high-burden diseases complete PADO assessments, which 10 priority paediatric formulations reach regulatory clearance and country uptake, and what measurable system improvements materialize in the 10 target countries, beginning with follow-up from the four South-East Asia pilot nations."],"sections":[]},"corrections":[],"country":null,"data":{"blocks":[{"description":{"ar":"أرقام مختارة لأهداف خارطة طريق 30 بحلول 2030 والمشروع التجريبي في جنوب شرق آسيا التي أوردتها شبكة GAP-f التابعة لمنظمة الصحة العالمية.","de":"Ausgewählte Zielzahlen der Strategie 30 bis 2030 und des Südostasien-Pilotworkshops laut WHO-Netzwerk GAP-f.","en":"Selected 30 by '30 Strategic Roadmap targets and South-East Asia regional pilot figures reported by WHO GAP-f.","es":"Cifras seleccionadas de los objetivos 30 para 2030 de la hoja de ruta estratégica y del taller piloto en Asia Sudoriental comunicados por GAP-f.","fr":"Chiffres sélectionnés des cibles 30 d'ici 2030 de la feuille de route stratégique et de l'atelier pilote en Asie du Sud-Est publiés par GAP-f.","pt":"Valores selecionados das metas 30 até 2030 do roteiro estratégico e do seminário piloto no Sudeste Asiático divulgados pela rede GAP-f.","tr":"DSÖ GAP-f tarafından bildirilen seçilmiş 30 by '30 Stratejik Yol Haritası hedefleri ve Güneydoğu Asya bölgesel pilot rakamları."},"id":"reported-figures","items":[{"basis":"target","label":{"ar":"عدد الأمراض عالية العبء المستهدفة بتقييم الأولويات بحلول 2030","de":"Krankheiten mit hoher Krankheitslast für Prioritätsbewertungen bis 2030","en":"High-burden diseases targeted for priority assessment by 2030","es":"Enfermedades de alta carga previstas para evaluación prioritaria hasta 2030","fr":"Maladies à forte charge ciblées pour une évaluation prioritaire d'ici 2030","pt":"Doenças de elevada carga previstas para avaliação prioritária até 2030","tr":"2030 yılına kadar öncelik değerlendirmesi hedeflenen yüksek yüklü hastalık sayısı"},"measure":{"aggregation":"stock","frequency":"annual","geography":"world","id":"g20261120-d7-who-1","periodRole":"reference-period","unitCode":"count"},"period":"2030","unit":"areas","value":10},{"basis":"target","label":{"ar":"عدد أدوية الأطفال ذات الأولوية المستهدف تسريعها بحلول 2030","de":"Vorrangige Kinderarzneimittel für beschleunigte Entwicklung bis 2030","en":"Priority paediatric medicines targeted for acceleration by 2030","es":"Medicamentos pediátricos prioritarios previstos para aceleración hasta 2030","fr":"Médicaments pédiatriques prioritaires ciblés pour accélération d'ici 2030","pt":"Medicamentos pediátricos prioritários previstos para aceleração até 2030","tr":"2030 yılına kadar hızlandırılması hedeflenen öncelikli pediatrik ilaç sayısı"},"measure":{"aggregation":"stock","frequency":"annual","geography":"world","id":"g20261120-d7-who-2","periodRole":"reference-period","unitCode":"count"},"period":"2030","unit":"items","value":10},{"basis":"target","label":{"ar":"عدد الدول المستهدفة بتعزيز منظومات أدوية الأطفال بحلول 2030","de":"Zielländer zur Stärkung pädiatrischer Arzneimittelökosysteme bis 2030","en":"Countries targeted for strengthened paediatric medicines ecosystems by 2030","es":"Países previstos para fortalecer ecosistemas de medicamentos pediátricos hasta 2030","fr":"Pays ciblés pour le renforcement des écosystèmes de médicaments pédiatriques d'ici 2030","pt":"Países previstos para reforço dos ecossistemas de medicamentos pediátricos até 2030","tr":"2030 yılına kadar pediatrik ilaç ekosistemi güçlendirilecek hedef ülke sayısı"},"measure":{"aggregation":"stock","frequency":"annual","geography":"world","id":"g20261120-d7-who-3","periodRole":"reference-period","unitCode":"count"},"period":"2030","unit":"countries","value":10},{"basis":"observed","label":{"ar":"عدد الدول التجريبية المشاركة في ورشة جنوب شرق آسيا في مايو 2026","de":"Teilnehmende Pilotländer am Südostasien-Workshop im Mai 2026","en":"Pilot countries represented at the May 2026 South-East Asia regional workshop","es":"Países piloto representados en el taller regional de Asia Sudoriental de mayo de 2026","fr":"Pays pilotes représentés à l'atelier régional d'Asie du Sud-Est en mai 2026","pt":"Países-piloto representados no seminário regional do Sudeste Asiático em maio de 2026","tr":"Mayıs 2026 Güneydoğu Asya bölgesel çalıştayına katılan pilot ülke sayısı"},"measure":{"aggregation":"stock","frequency":"monthly","geography":"asia","id":"g20261120-d7-who-4","periodRole":"reference-period","unitCode":"count"},"period":"2026-05","unit":"countries","value":4}],"methodology":{"ar":"تحتفظ الأرقام بالأفق الزمني والنطاق والتعريفات التي يحددها المصدر، وتُصنف الأهداف والبيانات المرصودة بحسب أساسها.","de":"Die Zahlen behalten Zeithorizont, Umfang und Definitionen der Quelle bei. Ziele und beobachtete Angaben sind nach ihrer Grundlage gekennzeichnet.","en":"Figures retain the source's stated roadmap horizon, scope and definitions. Targets and observed workshop participation are labeled by basis. No missing value is inferred.","es":"Las cifras conservan el horizonte, el alcance y las definiciones indicados por la fuente. Las metas y datos observados se identifican según su base.","fr":"Les chiffres conservent l'horizon, le périmètre et les définitions indiqués par la source. Les cibles et données observées sont qualifiées selon leur base.","pt":"Os valores mantêm o horizonte temporal, o âmbito e as definições indicados pela fonte. Metas e dados observados são identificados segundo a respetiva base.","tr":"Rakamlar kaynağın belirttiği yol haritası dönemini, kapsamı ve tanımları korur. Hedefler ve gözlenen çalıştay katılımı dayanaklarına göre etiketlenir. Eksik değerler çıkarımla tamamlanmaz."},"sourceUrls":["https://www.who.int/news/item/20-11-2026-better-medicines-for-every-child--gap-f-partners-accelerate-action-on-world-children-s-day"],"title":{"ar":"الأرقام الرئيسية المعلنة","de":"Wichtige gemeldete Kennzahlen","en":"Key reported figures","es":"Cifras clave comunicadas","fr":"Principaux chiffres déclarés","pt":"Principais valores reportados","tr":"Bildirilen temel rakamlar"},"type":"metrics","updatedAt":"2026-11-20T14:30:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026/data/reported-figures?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026/data/reported-figures?lang=en&format=json"},"id":"reported-figures"}],"data_types":["metrics"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-fce83b87-42b1-52c0-9f80-3b2cd829765b","event_period":"2026-11-20","event_period_basis":"event-or-reference-period","id":"who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026","image":null,"importance":0.6,"language":"en","modified_at":"2026-11-20T15:14:29+00:00","publication_basis":"publication-record","published_at":"2026-11-20T15:14:29+00:00","reading_minutes":4,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026","sources":[{"checkedAt":"2026-11-20","name":"World Health Organization, GAP-f Partners Accelerate Action on World Children's Day","publishedAt":"2026-11-20","url":"https://www.who.int/news/item/20-11-2026-better-medicines-for-every-child--gap-f-partners-accelerate-action-on-world-children-s-day"}],"summary":"The World Health Organization's Global Accelerator for Paediatric Formulations Network published an update on 20 November 2026 reaffirming its 2025-2030 roadmap and 30 by '30 targets across 10 diseases, 10 medicines and 10 countries, alongside a new South-East Asia pilot report.","text":"The World Health Organization's Global Accelerator for Paediatric Formulations Network published an update on 20 November 2026 reaffirming its 2025-2030 roadmap and 30 by '30 targets across 10 diseases, 10 medicines and 10 countries, alongside a new South-East Asia pilot report.\n\nThe World Health Organization and partners in the Global Accelerator for Paediatric Formulations Network, known as GAP-f, issued an update on 20 November 2026 to mark World Children's Day and review ongoing work to expand access to safe, effective and age-appropriate medicines for children. Hosted by WHO, the network brings together institutions across industry, academia, civil society and global health agencies. While noting progress in clinical research and formulation development, the update stressed that significant gaps persist in turning scientific advances into treatments that reach children in all settings.\n\nCentral to the network's multi-year work is the GAP-f Strategic Roadmap 2025-2030, anchored by a measurable framework called the 30 by '30 commitment. Under that commitment, GAP-f and its partners aim by 2030 to assess priorities across 10 high-burden diseases, accelerate the development and availability of 10 priority paediatric medicines and strengthen national paediatric medicines ecosystems in 10 countries. The update reaffirmed these three targets as shared benchmarks requiring sustained funding, regulatory coordination and country-level follow-through rather than isolated research projects.\n\nSylvie Briand, WHO chief scientist and acting assistant director-general for health systems, access and data, underscored the urgency of closing delays in child-focused drug development. She stated that children should not have to wait for medicines designed for their specific clinical needs, adding that aligning global priorities, strengthening paediatric clinical research and helping countries translate innovation into practical access are essential to achieving equitable health outcomes for every child.\n\nThe first operational pillar highlighted in the 20 November 2026 update centers on prioritization through WHO's Paediatric Drug Optimization process, known as PADO. Through PADO, GAP-f convenes technical experts and partner organizations to identify priority medicines and child-friendly formulations that address critical gaps in disease prevention and treatment. The network also pointed to a dedicated GAP-f product portfolio designed to consolidate these priorities into a single reference so that academic researchers, pharmaceutical developers and global health funders can concentrate resources on the highest-impact paediatric needs.\n\nThe second pillar focuses on generating stronger clinical evidence for children, who have historically been underrepresented in drug trials. GAP-f reported that it is working with partners to map global clinical research site capacity, promote the inclusion of children in clinical studies and encourage more efficient trial designs. To operationalize this effort, the network is assembling a package of clinical research resources combining information on global paediatric clinical trial sites, training materials on trial design and implementation, and cross-stakeholder recommendations on optimal study methodologies.\n\nThe third pillar addresses the transition from product development to country-level availability and clinical uptake. Developing an age-appropriate formulation does not guarantee that clinics and families can obtain or afford it without functioning regulatory pathways, procurement systems and national treatment guidelines. GAP-f stated that it works alongside WHO technical departments, Member States and partner organizations to diagnose bottlenecks in country access and support the practical introduction of optimal paediatric formulations.\n\nAs a concrete example of regional implementation, WHO highlighted a workshop convened in May 2026 with GAP-f partners in the South-East Asia region focused on strengthening paediatric medicines ecosystems. The gathering brought together national stakeholders from four pilot countries to examine structural barriers and identify workable solutions. Accompanying the World Children's Day update, a new report from the May 2026 workshop documents those findings and outlines practical opportunities for countries to align global prioritization and clinical evidence with local health-system realities.\n\nThe update framed paediatric medicines access as a lifecycle challenge spanning early prioritization, clinical trial execution, formulation engineering, regulatory review, financing and health-system delivery. Because no single institution controls every step of that chain, WHO described GAP-f as a coordination platform meant to keep governments, regulators, researchers, product developers, funders and civil society working toward shared milestones rather than fragmented initiatives.\n\nThe 20 November 2026 statement is a policy and program progress update rather than an announcement of a specific new drug approval or financing commitment. Measuring whether the 30 by '30 targets are achieved by 2030 will depend on transparent tracking of which 10 high-burden diseases complete PADO assessments, which 10 priority paediatric formulations reach regulatory clearance and country uptake, and what measurable system improvements materialize in the 10 target countries, beginning with follow-up from the four South-East Asia pilot nations.","title":"WHO GAP-f network outlines paediatric medicines priorities on World Children's Day","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"},{"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"},{"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"},{"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"},{"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"},{"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"},{"api_url":"https://newsverum.com/api/v1/articles/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"}],"url":"https://newsverum.com/en/news/who-gap-f-partners-accelerate-paediatric-medicines-world-childrens-day-2026"},"version":"1"}
